{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:10:30Z","timestamp":1785337830209,"version":"3.55.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007698","name":"University of Florida","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007698","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.omtm.2023.101179","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T07:57:23Z","timestamp":1702886243000},"page":"101179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Perspectives of the Friedreich ataxia community on gene therapy clinical trials"],"prefix":"10.1016","volume":"32","author":[{"given":"Shandra J.","family":"Trantham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzi A.","family":"Coker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Norman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Berthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry J.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sub","family":"Subramony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiangYang","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.omtm.2023.101179_bib1","first-page":"3","article-title":"Friedreich ataxia: the clinical picture","volume":"256","author":"Pandolfo","year":"2009","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.omtm.2023.101179_bib2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1006\/nbdi.1997.0139","article-title":"Frataxin Shows Developmentally Regulated Tissue-Specific Expression in the Mouse Embryo","volume":"4","author":"Jiralerspong","year":"1997","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.omtm.2023.101179_bib3","doi-asserted-by":"crossref","first-page":"14588","DOI":"10.1074\/jbc.273.23.14588","article-title":"Inhibitory effects of expanded GAA\u00b7TTC triplet repeats from intron I of the Friedreich ataxia gene on transcription and replication in\u00a0vivo","volume":"273","author":"Ohshima","year":"1998","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtm.2023.101179_bib4","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1212\/WNL.54.12.2322","article-title":"Unique origin and specific ethnic distribution of the Friedreich ataxia GAA expansion","volume":"54","author":"Labuda","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.omtm.2023.101179_bib5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1017\/S0317167100025464","article-title":"Clinical Description and Roentgenologic Evaluation of Patients with Friedreich's Ataxia","volume":"3","author":"Geoffroy","year":"1976","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.omtm.2023.101179_bib6","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/mds.22912","article-title":"Measuring the rate of progression in Friedreich ataxia: Implications for clinical trial design","volume":"25","author":"Friedman","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.omtm.2023.101179_bib7","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jacbts.2022.04.005","article-title":"Cardiovascular Research in Friedreich Ataxia: Unmet Needs and Opportunities","volume":"7","author":"Payne","year":"2022","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.omtm.2023.101179_bib8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jns.2011.05.023","article-title":"Mortality in Friedreich Ataxia","volume":"307","author":"Tsou","year":"2011","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.omtm.2023.101179_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.988914","article-title":"Routes of administration for adeno-associated viruses carrying gene therapies for brain diseases","volume":"15","author":"Zhou","year":"2022","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.omtm.2023.101179_bib12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/NEN.0b013e31827e5762","article-title":"Friedreich ataxia: Neuropathology revised","volume":"72","author":"Koeppen","year":"2013","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.omtm.2023.101179_bib13","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/jnen\/nlx087","article-title":"Friedreich Ataxia: Developmental Failure of the Dorsal Root Entry Zone","volume":"76","author":"Koeppen","year":"2017","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.omtm.2023.101179_bib14","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/ene.13843","article-title":"Developmental and neurodegenerative damage in Friedreich's ataxia","volume":"26","author":"Rezende","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.omtm.2023.101179_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213649","article-title":"Gene therapy as a potential therapeutic option for Duchenne muscular dystrophy: A qualitative preference study of patients and parents","volume":"14","author":"Landrum Peay","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2023.101179_bib16","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13023-019-1069-6","article-title":"Priorities when deciding on participation in early-phase gene therapy trials for Duchenne muscular dystrophy: a best-worst scaling experiment in caregivers and adult patients","volume":"14","author":"Paquin","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtm.2023.101179_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.1664","article-title":"Patients' and caregivers' maximum acceptable risk of death for non-curative gene therapy to treat Duchenne muscular dystrophy","volume":"9","author":"Peay","year":"2021","journal-title":"Mol. Genet Genomic Med."},{"key":"10.1016\/j.omtm.2023.101179_bib18","series-title":"FDA CBER OTAT Patient Focused Drug Development Listening Meeting Summary Report","year":"2023"}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050123002188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050123002188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T17:13:14Z","timestamp":1722100394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050123002188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2329050123002188"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2023.101179","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perspectives of the Friedreich ataxia community on gene therapy clinical trials","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2023.101179","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"101179"}}